Literature DB >> 35419720

Predicting conversion from MCI to AD by integration of rs-fMRI and clinical information using 3D-convolutional neural network.

Sima Ghafoori1, Ahmad Shalbaf2.   

Abstract

PURPOSE: Alzheimer's is the most common irreversible neurodegenerative disease. Its symptoms range from memory impairments to degradation of multiple cognitive abilities and ultimately death. Mild cognitive impairment (MCI) is the earliest detectable stage that happens between normal aging and early dementia, and even though MCI subjects have a chance of changing back to cognitively normal or even staying the same, there is a risk that their condition progresses to Alzheimer's disease (AD) annually. Therefore predicting AD among MCI subjects is pivotal for starting treatments at an opportune time in case of progression, and if staying stable is the case, the need for consistent medical observations would eliminate. Thus, we aim to diagnose possible conversion from MCI to AD by exploiting a class of deep learning (DL) methods called convolutional neural network (CNN).
METHODS: We proposed a three-dimensional CNN (3D-CNN) to combine and analyze resting-state functional magnetic resonance imaging (rs-fMRI), clinical assessment results, and demographic information to predict conversion from MCI to AD in an average 5-years interval. Initially, a 3D-CNN was developed based on fMRI single volumes of 266 samples from 81 subjects; then, we used neuron layers to combine clinical data with fMRI to improve the results.
RESULTS: At first, the CNN model demonstrated an AUC of 87.67% and an accuracy of 85.7%, then after combining clinical and rs-fMRI features, we observed the following improved scores: an AUC of 91.72%, an accuracy of 87.6%, a sensitivity of 75.58% and a specificity of 92.57%.
CONCLUSION: Our developed algorithm managed to predict prognosis from MCI to AD with high levels of accuracy, proving the potential of DL approaches in solving the matter and the efficiency of integrating clinical information with imaging according to the proposed method.
© 2022. CARS.

Entities:  

Keywords:  Alzheimer’s disease; Clinical information; Deep learning; Mild cognitive impairment; Resting state functional magnetic resonance imaging

Mesh:

Year:  2022        PMID: 35419720     DOI: 10.1007/s11548-022-02620-4

Source DB:  PubMed          Journal:  Int J Comput Assist Radiol Surg        ISSN: 1861-6410            Impact factor:   2.924


  21 in total

1.  A review of neuroimaging biomarkers of Alzheimer's disease.

Authors:  Tinu Varghese; R Sheelakumari; Jija S James; Ps Mathuranath
Journal:  Neurol Asia       Date:  2013       Impact factor: 0.183

Review 2.  Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond.

Authors:  Maju Mathew Koola
Journal:  Psychiatry Res       Date:  2020-08-18       Impact factor: 3.222

Review 3.  Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity.

Authors:  Judith Neugroschl; Sophia Wang
Journal:  Mt Sinai J Med       Date:  2011 Jul-Aug

4.  Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer's disease.

Authors:  Marion Tible; Åsa Sandelius; Kina Höglund; Ann Brinkmalm; Emmanuel Cognat; Julien Dumurgier; Henrik Zetterberg; Jacques Hugon; Claire Paquet; Kaj Blennow
Journal:  Neurology       Date:  2020-06-25       Impact factor: 9.910

Review 5.  Mild Cognitive Impairment.

Authors:  Angela M Sanford
Journal:  Clin Geriatr Med       Date:  2017-05-17       Impact factor: 3.076

6.  Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease.

Authors:  Davangere P Devanand; Xinhua Liu; Matthias H Tabert; Gnanavalli Pradhaban; Katrina Cuasay; Karen Bell; Mony J de Leon; Richard L Doty; Yaakov Stern; Gregory H Pelton
Journal:  Biol Psychiatry       Date:  2008-08-23       Impact factor: 13.382

Review 7.  Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.

Authors:  Qi Li; Siyu He; Yao Chen; Feng Feng; Wei Qu; Haopeng Sun
Journal:  Eur J Med Chem       Date:  2018-09-13       Impact factor: 6.514

Review 8.  Biomarkers for Alzheimer's Disease Diagnosis.

Authors:  Vasileios Mantzavinos; Athanasios Alexiou
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

9.  Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease.

Authors:  Balmiki Ray; Bryan Maloney; Kumar Sambamurti; Hanuma K Karnati; Peter T Nelson; Nigel H Greig; Debomoy K Lahiri
Journal:  Transl Psychiatry       Date:  2020-02-03       Impact factor: 6.222

Review 10.  The neuropathological diagnosis of Alzheimer's disease.

Authors:  Michael A DeTure; Dennis W Dickson
Journal:  Mol Neurodegener       Date:  2019-08-02       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.